Candel Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
CADL$9.35-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| THREE MONTHS ENDEDSEPTEMBER 30, | NINE MONTHS ENDEDSEPTEMBER 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating expenses: | ||||
| Research and development | $5,416 | $5,845 | $14,497 | $17,248 |
| General and administrative | 3,341 | 3,016 | 10,733 | 10,825 |
| Total operating expenses | 8,757 | 8,861 | 25,230 | 28,073 |
| Loss from operations | (8,757) | (8,861) | (25,230) | (28,073) |
| Other income (expense): | ||||
| Grant income | — | 12 | — | 36 |
| Interest income | 236 | 502 | 796 | 1,666 |
| Interest expense | (487) | (669) | (1,700) | (1,922) |
| Change in fair value of warrant liability | (1,638) | 581 | (14,970) | 1,449 |
| Total other income (expense), net | (1,889) | 426 | (15,874) | 1,229 |
| Net loss and comprehensive loss | $(10,646) | $(8,435) | $(41,104) | $(26,844) |
| Net loss per share, basic and diluted | $(0.33) | $(0.29) | $(1.35) | $(0.93) |
| Weighted-average common shares outstanding, basic and diluted | 32,013,569 | 28,919,810 | 30,369,129 | 28,919,810 |
Candel ThErapeutics, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.